NCT03908814View on ClinicalTrials.gov

Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

April 27, 2019

Primary Completion Date

November 26, 2021

Study Completion Date

April 26, 2022

Conditions
Advanced Tumors
Interventions
DRUG

Whole Human Anti-PD-L1 Antibody Injection (LDP)

Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.

Trial Locations (1)

Unknown

RECRUITING

Dragonboat Biopharmaceutical,Co.,Ltd, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

lead

Dragonboat Biopharmaceutical Company Limited

INDUSTRY